

Lexaria Bioscience	LXX	CSE	\$1.52	76	\$116	4	0	\$112	\$125	0	0	\$4	30.6	34.2	0		-5
LiveWell Canada	LWWL	TSXV	\$0.74	130	\$96	4	16	\$108	\$113	0	28	\$16	6.0	6.9	0		-2
Choom Holdings	CHOO	CSE	\$0.54	179	\$97	7	1	\$91	\$110	0	90	\$96	1.0	14.8	0		-2
Cannex Capital	CNNX	CSE	\$0.91	87	\$79	13	12	\$78	\$82	0	30	\$31	2.6	2.4	2		0
Hempco Food	HEMP	TSXV	\$1.06	61	\$65	5	1	\$61	\$62	2	4	\$10	6.5	6.6	1		-1
Wildflower Brands	SUN	CSE	\$0.66	64	\$42	1	9	\$50	\$54	0	2	-\$6	-7.0	-7.7	1		-1
Tinley Beverage	TNY	CSE	\$0.58	88	\$51	7	0	\$44	\$50	0	0	\$7	7.3	7.3	0		-1
Cordovacann	CDVA	CSE	\$1.06	40	\$42	1	0	\$41	\$43	0	0	\$1	42.4	15.3	0		-1
Alternate Health	AHG	CSE	\$0.52	54	\$28	1	8	\$35	\$37	0	6	-\$1	-40.1	25.0	1		-4
Inner Spirit (dispensaries)	ISH	CSE	\$0.22	174	\$38	7	3	\$34	\$37	3	1	\$8	4.8	38.3	1		-1
Phivida	VIDA	CSE	\$0.72	60	\$43	16	1	\$28	\$20	0	0	\$15	2.9	2.3	0		-3
New Age Brands	NF	CSE	\$0.07	317	\$22	1	2	\$23	\$29	0	5	\$4	5.5	-27.7	0		-1
Kojos Beverage	KBEV	CSE	\$0.41	50	\$21	1	1	\$21	\$22	0	1	\$1	20.5	21.5	0		-1
Naturally Splendid	NSP	TSXV	\$0.16	102	\$16	1	2	\$17	\$15	2	2	\$3	5.4	4.3	1		-2
Empower Clinics	EPW	CSE	\$0.12	75	\$9	0	4	\$13	\$17	0	0	-\$4	-2.3	-3.2	0		-1
Cannas Medtech	MTEC	CSE	\$0.31	41	\$13	1	0	\$12	\$12	0	0	\$1	12.7	12.5	0		-2
Global Cannabis Apps	APP	CSE	\$0.14	88	\$12	3	1	\$10	\$14	0	0	\$2	6.2	7.9	0		-2
Neutrisci	NU	TSXV	\$0.09	100	\$9	0	1	\$10	\$8	0	0	-\$1	-9.0	9.0	0		-1
Alliance Growers	ACG	CSE	\$0.11	69	\$8	1	0	\$7	\$9	0	0	\$1	7.6	9.7	0		-1

Royalty / Finance Focus > check financial statements as numbers below do not report investments in other companies

Canopy Rivers	RIV	TSXV	\$3.93	171	\$672	106	2	\$568	\$560	0	0	\$104	6.5	6.2	0	35	-1
Origin House	OH	CSE	\$7.35	55	\$404	78	57	\$383	\$472	8	11	\$40	10.1	28.4	7		-10
Auxly Cannabis	XLY	TSXV	\$0.86	565	\$486	244	111	\$353	\$426	3	21	\$157	3.1	3.6	1	165	-5
iAnthus Capital	IAN	CSE	\$6.05	58	\$351	50	49	\$350	\$340	15	31	\$47	7.4	13.4	1		-12
Australis Capital	AUSA	CSE	\$1.08	120	\$130	17	1	\$114	\$155	0	3	\$19	6.8	6.0	0		-2
ICC International Cannabis	WRLD	CSE	\$0.49	145	\$71	1	0	\$70	\$75	0	0	\$1	71.1	71.1	0		-1
LGC Capital	LG	TSXV	\$0.12	375	\$45	15	4	\$34	\$42	0	0	\$11	4.2	4.9	0		-14
Captor Capital	CPTR	CSE	\$1.30	39	\$51	42	3	\$12	\$17	0	47	\$86	0.6	2.1	0		-6
High Hampton Holdings	HC	CSE	\$0.41	77	\$32	20	0	\$12	\$16	0	5	\$25	1.3	1.4	0		-3
Fincanna Capital	CALI	CSE	\$0.16	66	\$11	6	0	\$5	\$6	0	0	\$6	1.8	2.0	0		-1

Cannabis R&D - Science / Pharma Focus

TABLE 3 of 3			CDN \$ (MM) From Most Recent Qtr Financials														
			Nov 30/18	Shares	Market	Cash & A/R		Enterprise	EV	Organic	Bldg &	Adjusted	Price to	PABV		2019 Rev	Net Income
			Share Price	Out	Cap (Mcap)	+ GIC's	Debt	Value	Nov 15	Inventory	Equip	Book Value	Book Value	Nov 15	Revenue	Estimate	or Loss
Company (click for website)	Symbol	EX		(MM)	(\$MM)	(\$MM)	(\$MM)	(EV)	2018	(\$MM)	(\$MM)	(ABV)	(PABV)	2018	(\$MM)	(\$MM)	(\$MM)
Tetra Bio-Pharma	TBP	CSE	\$1.04	160	\$166	14	5	\$157	\$149	0	0	\$9	18.5	17.6	0		-3
Kalytera Therapeutics	KALY	TSXV	\$0.09	255	\$23	1	61	\$82	\$92	0	0	-\$59	-0.4	-0.4	0		-14
InMed Pharmaceuticals	IN	CSE	\$0.52	171	\$89	25	1	\$65	\$70	0	0	\$24	3.7	3.9	0		-3
Canntab Therapeutics	PILL	CSE	\$1.13	25	\$28	4	0	\$24	\$28	0	0	\$4	7.1	8.0	0		-2
Aequus Pharmaceuticals	AQS	TSXV	\$0.19	77	\$15	2	0	\$13	\$13	0	0	\$2	7.3	13.9	0		-1
Revive Therapeutics	RVV	TSXV	\$0.12	58	\$7	1	0	\$6	\$8	0	0	\$1	7.0	9.3	0		0

Danny Deadlock, MicroCap Equity Analyst / MicroCap.com Publisher (1998) - Alberta
www.linkedin.com/in/dannydeadlock

[Facebook.com/MicroCap](https://www.facebook.com/MicroCap)
[Twitter.com/MicroCap_com](https://twitter.com/MicroCap_com)

If a company wishes to add 2019 revenue estimates or if you have an analyst forecast (pdf), please email - micropcap@gmail.com

Disclosure / Disclaimer: Danny Deadlock (MicroCap.com) is an independent analyst and has no affiliation with public companies. He receives no compensation in ANY form from anyone. But he may be a shareholder of any of these companies through market purchases using his own funds. He may be an active buyer or seller at any given time this report is in circulation.